NasdaqGM:SMMTBiotechs
Summit Therapeutics Links Ivonescimab Brain Metastases Data To November PDUFA
Summit Therapeutics presented new Phase III data on ivonescimab at the 2026 European Lung Cancer Congress in EGFR mutated NSCLC.
The data highlighted improved intracranial progression free survival, including in patients with brain metastases.
The company has submitted a Biologics License Application to the FDA, with a PDUFA decision date set for November.
Summit Therapeutics, trading as NasdaqGM:SMMT, is drawing attention after sharing these late stage results alongside a confirmed FDA...